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ing rates of NI per 1000 cases ranged from 11 to 175 per year for
ofﬁce-based encounters and 0 to 311 for hospital-based encoun-
ters. Adamantane prescribing rates ranged from 23 to 194 for
ofﬁce-based encounters and 5 to 172 for hospital-based en-
counters. Odds ratios of adamantanes rather than NIs were 26.6
(P < 0.0001) for 1999, 0.034 for 2000, 0.011 for 2001, 0.058 for
2002, 0.002 for 2003, 0.178 for 2004 (p < 0.001). Whites (OR:
9.4, p < 0.001), females (OR: 1.8. p < 0.001), patients under 55
(OR: 0.4–0.53, p < 0.001), and patients from the West (OR:
2.7–33.9, p < 0.001) were most likely to get adamantanes. CON-
CLUSION: NI usage slowly increased from 1999–2005. Ofﬁce-
based encounters had a greater rate of prescriptions for
adamantanes than hospital-based encounters. In months other
than ﬂu season patients were less likely (OR: 0.06, p < 0.001) to
get adamantanes. General practitioners were less likely (OR: 0.5,
p < 0.001) to prescribe adamantanes than other specialties.
Patient age, race, sex, physician specialty, and geographic region
were signiﬁcantly related to prescribing patterns. In 2005,
patients were more likely to get adamantanes in spite of high
incidence of adamantane resistant viruses.
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OBJECTIVE: To estimate the number of patients with potential
major, moderate or major/moderate drug-drug interactions
(DDI) between oral antipsychotics and coprescribed drugs
within a managed care population (MCP). METHODS: Litera-
ture and drug information resources were used to identify and
classify clinical severity of potential antipsychotic DDIs based
on cytochrome P450 metabolism of antipsychotics and copre-
scribed drugs. PHARMetrics pharmacy claims for one year
(June 2004 zC July 2005) from individuals with antipsychotic
claims (including oral risperidone, olanzapine, quetiapine,
ziprasidone, aripiprazole, clozapine, oral haloperidol and per-
phenazine) were evaluated. Patients with 10 days of overlap
with a potentially interacting drug of severity grade 1 (major),
2 (moderate) or 4 (major/moderate) were identiﬁed. Drug Facts
& Comparisons severity grading scale was used to determine
drugs that met these criteria. Results were extrapolated to
provide a population-based prediction of the risk for potential
DDIs. Recent national market-share (MS) data (IMS prescrip-
tion audit 4Q06) for each antipsychotic were multiplied by the
percentage of potential projected interactions to determine the
number of patients at risk for DDIs in a cohort of 10,000
patients prescribed antipsychotics. RESULTS: Of the 73,562
patients who met study inclusion criteria, 8551 (11.6%)
patients had at least one potential DDI of severity grade 1, 2 or
4. Depending on the antipsychotic dispensed, percentage of
potential DDIs ranged from 0% to 26.8%. Applied to a cohort
of 10,000 patients, over 1162 (11.6%) patients could poten-
tially experience a grade 1, 2 or 4 DDI. Oral risperidone
(26.8% MS) had the highest potential for DDIs (n = 676) and
quetiapine (30.4% MS) had the second highest potential for
DDIs (n = 137). Ziprasidone (5.7% MS) had no potential P450
DDI interactions of severity grade 1, 2 or 4. CONCLUSION:
Prevalence of potentially serious DDIs due to interactions with
cytochrome P450 metabolic activity is high in patients being
treated with antipsychotics.
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OBJECTIVE: The objectives of this analysis were to: Identify a
population of schizophrenia patients treated within a commer-
cial managed care environment. Describe and compare the
prevalence of conditions associated with metabolic syndrome in
patients treated with antipsychotics agents. METHODS: Using
integrated medical and pharmacy claims data (obtained from
the IMS/Pharmetrics Patient-centric Database), patients were
included in this analysis based on the presence of a diagnosis of
schizophrenia (ICD-9 code 295.*) in 2005. Clinical and eco-
nomic information related to the treatment of schizophrenia
were captured using Episode Treatment Group™ (ETG™)
episode-building software. RESULTS: In 2005, 8594 schizo-
phrenia patients were identiﬁed; within this population, the
average age was 45.7 years and 46% was male. Co-morbid
conditions included bipolar disorders (in 23.7% of patients),
anxiety disorder (12.7%), substance dependence (11.7%), and
depression (7.9%). Overall (among the entire identiﬁed patient
population), 75.6% of patients used antipsychotics; 57.4% used
only atypical agents, 9.1% used only conventional agents and
9.1% used both. Overall, 48.6% of patients had at least one of
the following conditions, considered markers for metabolic
syndrome: diabetes, hyperlipidemia, hypertension, or obesity.
Among patients treated with antipsychotics, prevalence of these
conditions was lowest in those treated only with atypical agents
(46.5% with at least one condition), higher in patients treated
only with conventional agents (55.5% with at least one
condition), and highest in patients with use of both classes of
antipsychotic agents. CONCLUSION: The schizophrenia popu-
lation observed in this analysis reﬂected a lower prevalence
of presumed metabolic syndrome in groups treated with
atypical antipsychotic agents. This observation contradicts other
research. This disparity may be attributable to differences in
patient demographics or other confounding factors, but none-
theless warrants further study.
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OBJECTIVE: To examine a sample of patients admitted to hos-
pitals with drug abuse for some inpatient treatment in order to
look for trends that may lead to a better understanding of the
data and of which groups seem to be most at risk for this
ailment. METHODS: Data were taken from a ten percent
sample of the National Inpatient Sample from 2004. A data
sample of 7903 inpatients from 2004 was organized, plotted,
graphed, and put into tables in order to best understand the
patterns and variances. Logistic regression models were created
to compare variables and help to predict age and mortality of
the inpatients. The data were preprocessed to include only the
most frequently occurring diagnosis and procedure codes.
RESULTS: Frequency of cases of drug abuse showed spikes
near the ages of 40 and 80, with the African Americans and
males dominant at the 40 spike and the Caucasians and males
at the 80 spike. Code variables for rehabilitation, blood trans-
fusion, respiratory intubation, hypertension, heart disease,
congestive heart failure, urinary tract infection, cardiac dys-
rhythmias, pulmonary disease, ﬂuid disorder, CT head
scan, gastrointestinal endoscopy, psychiatric therapy, physical
Abstracts A109
therapy, and various mental disorders were combined with
these results to create a model that is almost 80 percent accu-
rate. Mortality can be predicted using the variables vascular
catheterization, respiratory intubation, and coronary athero-
sclerosis with an accuracy of 63.4 percent. CONCLUSION: A
bimodal trend in the age of drug abusers suggests two different
types of drug abuse. The most likely explanation is the abuse of
recreational drugs around the age of 40 and the abuse or
misuse of prescription drugs around the age of 80. Mortality
can be predicted so accurately using only three variables
because these procedures are associated with the highest prob-
ability of death.
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OBJECTIVE: The purpose of this study was to evaluate the
relative efﬁcacy of different atypical antipsychotic medications
(AAPs) in the treatment of schizophrenia using a Bayesian mixed
treatment comparison (MTC) model. METHODS: The Cochran
central register of controlled trials and PubMed database were
searched to identify randomized controlled clinical trials assess-
ing the efﬁcacy of AAPs (olanzapine, risperidone, clozapine,
aripiprazole, quetiapine, ziprasidone) in the treatment of schizo-
phrenia. Studies were included if they used change in the Positive
and Negative Syndrome Scale (PANSS) as an outcome measure.
Findings from these studies were analyzed using Bayesian meta-
analysis of direct and indirect comparisons. Both, ﬁxed and
random effects models were employed in the analysis. RESULTS:
Twenty eight trials were identiﬁed, which included a total of
6023 patients. The ﬁxed effects model indicated that clozapine
and olanzapine had signiﬁcantly greater improvements on the
PANSS overall scale (median change from baseline: 19.4 (95%
credible interval [CrI] 19.2–19.5) and 19.3 (95% [CrI] 19.3–
19.4) for clozapine and olanzapine respectively) than all other
AAPs. In the rank order analysis, clozapine had a 82% probabil-
ity of being the best treatment. Clozapine showed signiﬁcantly
more improvements on the positive subscale (mean change from
baseline 5.4 (95% [CrI] 5.2–5.5), and 100% probability of being
the best treatment). On the negative subscale, clozapine and
olanzapine showed signiﬁcantly more improvements than other
APPs. However, the random effects model found no signiﬁcant
differences among the AAPs in the magnitude of improvements
on the PANSS overall scale, as well as the positive and negative
subscales. This may be due to substantial inter-study variation.
CONCLUSION: Using a ﬁxed effects model, clozapine and olan-
zapine were found to be signiﬁcantly more efﬁcacious, but these
ﬁndings were not supported by the random effects analysis. More
direct comparisons are needed to make deﬁnitive conclusions
about the relative efﬁcacy of these agents.
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OBJECTIVE: One way to evaluate effectiveness of antipsychot-
ics is to measure frequency of symptomatic relapses in patients
with schizophrenia. The occurrence and duration of hospital-
izations are important markers of potential relapses. This study
assessed differences in days hospitalized among schizophrenic
patients receiving paliperidone extended-release tablets (pali-
peridone ER) during the 52-week open-label extension (OLE)
phases of three double-blind (DB) trials as compared to treat-
ment as usual (TAU) in the six months following the OLE
phases of these trials. METHODS: Data on resource use was
collected through retrospective chart review. Average number of
hospital days during OLE and TAU phases was calculated
including the use of bootstrap resampling methods to assess
statistical signiﬁcance of differences. Total person years were
calculated for OLE and TAU phases to account for different
lengths of observation. Antipsychotic use during TAU phase was
also evaluated. Paliperidone ER was not commercially available
during TAU phase. RESULTS: In this analysis, patients (n = 71)
were from the US (31.0%), Canada (21.1%) and Malaysia
(47.9%). Mean (SD) patient age was 37.9 (10.5) years; and
the majority were male (70.4%). During the OLE, the mean
paliperidone ER treatment duration (SD) was 212.9 (141.2)
days, and the mean dose was 11.4 (2.1) mg. Patients experi-
enced an average of 5.0 and 15.3 hospital days per person year
in OLE and TAU phases, respectively, indicating that a mean
increase of 10.3 days of hospitalization was observed during
TAU phase (95%CI 2.3,19.2, P = 0.006). During TAU phase,
the treatments received were second-generation antipsychotics
(SGAs) (52.1%), ﬁrst-generation antipsychotics (FGAs) (9.9%),
or both FGAs and SGAs (14.1%). CONCLUSION: Patients
discontinuing paliperidone ER after the OLE phases experi-
enced more hospital days compared to the OLE phases where
they received paliperidone ER. Whether this increase in hospital
days is associated with a greater frequency or severity of
relapses remains to be tested.
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OBJECTIVE: This study used signal detection methods to iden-
tify the optimal magnitude of early non-response to antipsychotic
medication at various early time points that best predicts subse-
quent non-response at eight weeks, using different criteria of
subsequent non-response. This analysis was implemented sepa-
rately for schizophrenia patients with at least moderate sym-
ptom severity, and for patients with lesser symptom severity.
METHODS: Data were pooled from ﬁve randomized, double-
blind clinical trials of atypical antipsychotics in the treatment of
patients with schizophrenia, schizoaffective disorder, or schizo-
phreniform disorder, and included 1437 patients (n = 1137 with
at least moderate symptom severity; n = 300 with lesser symptom
severity). Signal detection methods were used to identify the
optimal response threshold based on improvement from baseline
on the Positive and Negative Syndrome Scale (PANSS) total score
at different early time points (Week 1 to Week 4 of treatment) to
predict subsequent non-response at eight weeks, while control-
ling the false positive rate at 30% or less. RESULTS: The optimal
thresholds for patients with at least moderate symptom severity
were 7–12% at Week 1, 14–23% at Week 2, 20–38% at Week 3,
and 26–45% at Week 4. For patients with lesser symptom sever-
ity, the optimal thresholds were 3–4% at Week 1, 7–12% at
Week 2, 6–14% at Week 3, and 15–20% at Week 4. Results were
validated using data from another clinical trial. CONCLUSION:
Different early response thresholds appear to maximize identiﬁ-
cation of subsequent non-responders to antipsychotic medica-
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